SlideShare ist ein Scribd-Unternehmen logo
1 von 18
Downloaden Sie, um offline zu lesen
More than just a potential
breakthrough treatment
for many cancers
June 2015
22
Critical Outcome Technologies Inc.
Rapidly developing
targeted therapies to
better meet the needs
of patients
 TSX-V: COT
 OTCQB: COTQF
3
Highlights
1
2
3
COTI-2 – lead program in oncology entering
Phase 1 clinical trial in 2015
CHEMSAS – proprietary drug discovery
engine using machine-based learning
Strong pipeline of opportunities in
oncology and other therapeutic areas
4
COTI-2: a promising advance
 Potential breakthrough
treatment for many cancers
 Effective against many
common cancers with a
p53 gene mutation
 > 50% of all human cancers
have a p53 mutation
(eg. ~ 95% of serous ovarian cancers)
5
COTI-2 background
N
N
N
H
S
N
N
N
 3rd generation
Thiosemicarbazone
 A small molecule
discovered by our
CHEMSAS process
 Engineered for low
toxicity and easily
synthesized in 3 steps
 Demonstrates strong in
vitro and in vivo activity
5
6
COTI-2: first- and best-in-class potential
 Novel p53-dependent mechanism of action
 Orally bio-available and effective at low dose
 Low toxicity in preclinical development
 Opportunity for single agent and combination
therapy
 Strong IP protection in place
7
COTI-2 and tumor volumes
Tumors significantly reduced by COTI-2 in all
treatment groups relative to vehicle control
8
COTI-2 reduces p53 resistant protein levels
 COTI-2 significantly reduces p53 mutant protein levels and
significantly increases wild-type p53 protein levels in TOV-
112D cells likely by inducing a conformational change
•(*) Significant
difference in p53
protein levels
between COTI-2
treated and untreated
cells (control)
Mutant p53 Levels in the
presence/absence of
COTI-2
0
20
40
60
80
100
TOV-112D H460
MeanFluorescenceIntensity(ArbitraryUnits)
Cell Line
Control
COTI-2
*
9
COTI-2: effects on p53 protein levels
 COTI-2 has no significant effect on p53 protein levels in the
H460 cell line, which do not carry the mutant p53 protein
•(*) Significant difference
in p53 protein levels
between COTI-2 treated
and untreated cells
(control)
Wild-type p53 Levels in
the Presence/Absence of
COTI-2
0
20
40
60
80
100
120
TOV-112D H460
MeanFluorescenceIntensity(ArbitraryUnits)
Cell Line
Control
COTI-2
*
10
MD Anderson relationship
10
 Confirmed COTI-2’s novel p53 dependent MOA
 Confirmed selective & potent anti-cancer activity
 Identified effective dosage 60% lower than in prior animal
experiments
11
COTI-2: the pathway to the clinic
 Granted orphan drug status for ovarian cancer by FDA in
June 2014
 Completed final pre-clinical studies
 Signed LOI with MD Anderson for Phase 1 clinical
development
 Grant of Investigational New Drug status in May 2015
 Commence Phase 1 clinical trial in 3rd quarter of calendar
2015
12
COTI-2: next steps
12
Complete Phase 1: 46 patients in
gynecologic cancers
Expand indications and
combination therapies
Phase 2: add value – create
partnerships
1313
 Proprietary, machine
learning (AI) based
drug discovery
platform technology
 Big Data analysis
solutions
Building a robust pipeline with CHEMSAS®
14
Costly failed attempts
occur quickly & cheaply
in computer simulations,
not the ‘wet lab’
Increased probability of
clinical & commercial
success
Database driven
computational
replication of
traditional
‘wet lab’ drug
discovery process
14
Advantages of CHEMSAS®
15
Drugs in our pipeline
Therapy
Library
/Compound
Target CHEMSAS Lead
Selection
Synthesis Preclinical Phase 1
Oncology
COTI-2
AML
Colon
Small Cell Lung Cancer Library
COTI-219
COTI-4
COTI-58
6 other leads
Plus projects for MRSA, Multiple sclerosis, Alzheimer’s, and HIV Integrase Inhibitors
16
Summary
1
2
3
COTI-2 – lead program in oncology entering
Phase 1 clinical trial in 2015
CHEMSAS – proprietary drug discovery
engine using machine-based learning
Strong pipeline of opportunities in
oncology and other therapeutic areas
17
When used anywhere in this presentation, whether oral or written, the words expects, believes,
anticipates, estimates and similar expressions are intended to identify forward-looking
statements. Forward-looking statements may include statements addressing future financial and
operating results of Critical Outcome Technologies Inc. (COTI).
COTI bases these forward-looking statements on its current expectations about future events.
Such statements are subject to risks and uncertainties including, but not limited to, the
successful implementation of COTI’s strategic plans, the acceptance of new products, the
obsolescence of existing products, the resolution of potential patent issues, competition,
changes in economic conditions, and other risks described in COTI’s public documents such as
press releases and filings with the Toronto Stock Exchange and the Ontario Securities
Commission.
All forward-looking statements are qualified in their entirety by the cautionary statements
included in this document and such filings. These risks and uncertainties could cause actual
results to differ materially from results expressed or implied by forward-looking statements
contained in this presentation. These forward-looking statements speak only as of the date of
this presentation.
Disclaimer
Follow CriticalOutcome on Twitter,
Facebook, YouTube and SlideShare

Weitere ähnliche Inhalte

Was ist angesagt?

Asco pfizer analyst call slides final
Asco pfizer analyst call slides  finalAsco pfizer analyst call slides  final
Asco pfizer analyst call slides finalpfizer_ir
 
PharmaMar-corporate-presentation
PharmaMar-corporate-presentationPharmaMar-corporate-presentation
PharmaMar-corporate-presentationVincenzo Esposito
 
Cancer growth inhibitors market & clinical pipeline analysis
Cancer growth inhibitors market & clinical pipeline analysisCancer growth inhibitors market & clinical pipeline analysis
Cancer growth inhibitors market & clinical pipeline analysisKuicK Research
 
Targeted genomic sequencing assay for comprehensive molecular characterizatio...
Targeted genomic sequencing assay for comprehensive molecular characterizatio...Targeted genomic sequencing assay for comprehensive molecular characterizatio...
Targeted genomic sequencing assay for comprehensive molecular characterizatio...Saba Anwer, MPH, MBA
 
Pareto Securities’ 8th Annual Healthcare Conference
Pareto Securities’ 8th Annual Healthcare ConferencePareto Securities’ 8th Annual Healthcare Conference
Pareto Securities’ 8th Annual Healthcare Conferencetargovax2017
 
Global Transactions in Pharma/Biotech
Global Transactions in Pharma/BiotechGlobal Transactions in Pharma/Biotech
Global Transactions in Pharma/BiotechPharma Intelligence
 
1711 3 q presentation v7 uten backup
1711 3 q presentation v7 uten backup1711 3 q presentation v7 uten backup
1711 3 q presentation v7 uten backuptargovax2017
 
Targovax presentation december 2017 carnegie
Targovax presentation december 2017 carnegieTargovax presentation december 2017 carnegie
Targovax presentation december 2017 carnegietargovax2017
 
Q1 2017 Presentation
Q1 2017 PresentationQ1 2017 Presentation
Q1 2017 Presentationtargovax2017
 
1708 2 q presentation v7 uten backups
1708 2 q presentation v7 uten backups1708 2 q presentation v7 uten backups
1708 2 q presentation v7 uten backupstargovax2017
 
1706 ir deck full w_appendix v1_cmd_v6_uten appendix
1706 ir deck full w_appendix v1_cmd_v6_uten appendix1706 ir deck full w_appendix v1_cmd_v6_uten appendix
1706 ir deck full w_appendix v1_cmd_v6_uten appendixtargovax2017
 
10th european life science ceo forum
10th european life science ceo forum10th european life science ceo forum
10th european life science ceo forumtargovax2017
 
1711 3 q presentation final
1711 3 q presentation final1711 3 q presentation final
1711 3 q presentation finaltargovax2017
 
Redeye Fight Cancer Seminar
Redeye Fight Cancer SeminarRedeye Fight Cancer Seminar
Redeye Fight Cancer Seminartargovax2017
 
Arming the patient's immune system to fight cancer
Arming the patient's immune system to fight cancerArming the patient's immune system to fight cancer
Arming the patient's immune system to fight cancertargovax2017
 
Stem cells: Information environment
Stem cells: Information environmentStem cells: Information environment
Stem cells: Information environmentArete-Zoe, LLC
 
1706 ir deck full w_appendix v1_cmd_v12_nett
1706 ir deck full w_appendix v1_cmd_v12_nett1706 ir deck full w_appendix v1_cmd_v12_nett
1706 ir deck full w_appendix v1_cmd_v12_netttargovax2017
 

Was ist angesagt? (20)

A promising advance for many cancers
A promising advance for many cancersA promising advance for many cancers
A promising advance for many cancers
 
2016 Annual General & Special Meeting of Shareholders
2016 Annual General & Special Meeting of Shareholders2016 Annual General & Special Meeting of Shareholders
2016 Annual General & Special Meeting of Shareholders
 
GALT Presentation
GALT PresentationGALT Presentation
GALT Presentation
 
Asco pfizer analyst call slides final
Asco pfizer analyst call slides  finalAsco pfizer analyst call slides  final
Asco pfizer analyst call slides final
 
PharmaMar-corporate-presentation
PharmaMar-corporate-presentationPharmaMar-corporate-presentation
PharmaMar-corporate-presentation
 
Cancer growth inhibitors market & clinical pipeline analysis
Cancer growth inhibitors market & clinical pipeline analysisCancer growth inhibitors market & clinical pipeline analysis
Cancer growth inhibitors market & clinical pipeline analysis
 
Targeted genomic sequencing assay for comprehensive molecular characterizatio...
Targeted genomic sequencing assay for comprehensive molecular characterizatio...Targeted genomic sequencing assay for comprehensive molecular characterizatio...
Targeted genomic sequencing assay for comprehensive molecular characterizatio...
 
Pareto Securities’ 8th Annual Healthcare Conference
Pareto Securities’ 8th Annual Healthcare ConferencePareto Securities’ 8th Annual Healthcare Conference
Pareto Securities’ 8th Annual Healthcare Conference
 
Global Transactions in Pharma/Biotech
Global Transactions in Pharma/BiotechGlobal Transactions in Pharma/Biotech
Global Transactions in Pharma/Biotech
 
1711 3 q presentation v7 uten backup
1711 3 q presentation v7 uten backup1711 3 q presentation v7 uten backup
1711 3 q presentation v7 uten backup
 
Targovax presentation december 2017 carnegie
Targovax presentation december 2017 carnegieTargovax presentation december 2017 carnegie
Targovax presentation december 2017 carnegie
 
Q1 2017 Presentation
Q1 2017 PresentationQ1 2017 Presentation
Q1 2017 Presentation
 
1708 2 q presentation v7 uten backups
1708 2 q presentation v7 uten backups1708 2 q presentation v7 uten backups
1708 2 q presentation v7 uten backups
 
1706 ir deck full w_appendix v1_cmd_v6_uten appendix
1706 ir deck full w_appendix v1_cmd_v6_uten appendix1706 ir deck full w_appendix v1_cmd_v6_uten appendix
1706 ir deck full w_appendix v1_cmd_v6_uten appendix
 
10th european life science ceo forum
10th european life science ceo forum10th european life science ceo forum
10th european life science ceo forum
 
1711 3 q presentation final
1711 3 q presentation final1711 3 q presentation final
1711 3 q presentation final
 
Redeye Fight Cancer Seminar
Redeye Fight Cancer SeminarRedeye Fight Cancer Seminar
Redeye Fight Cancer Seminar
 
Arming the patient's immune system to fight cancer
Arming the patient's immune system to fight cancerArming the patient's immune system to fight cancer
Arming the patient's immune system to fight cancer
 
Stem cells: Information environment
Stem cells: Information environmentStem cells: Information environment
Stem cells: Information environment
 
1706 ir deck full w_appendix v1_cmd_v12_nett
1706 ir deck full w_appendix v1_cmd_v12_nett1706 ir deck full w_appendix v1_cmd_v12_nett
1706 ir deck full w_appendix v1_cmd_v12_nett
 

Ähnlich wie More than just a potential BREAKTHROUGH treatment for many cancers

180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5targovax2017
 
Critical Outcome Technologies - Investor Presentation - June 2013
Critical Outcome Technologies - Investor Presentation - June 2013Critical Outcome Technologies - Investor Presentation - June 2013
Critical Outcome Technologies - Investor Presentation - June 2013Critical Outcome Technologies Inc.
 
Tomorrows path-to-improved-early-phase-oncology-drug-development
Tomorrows path-to-improved-early-phase-oncology-drug-developmentTomorrows path-to-improved-early-phase-oncology-drug-development
Tomorrows path-to-improved-early-phase-oncology-drug-developmentQuintiles
 
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...Laura Berry
 
1810 3 q-2018-presentation-v7
1810 3 q-2018-presentation-v71810 3 q-2018-presentation-v7
1810 3 q-2018-presentation-v7targovax2017
 
Vital Signs Edition #3
Vital Signs   Edition #3Vital Signs   Edition #3
Vital Signs Edition #3ScottJordan
 
March 2017 Corporate Presentation
March 2017 Corporate PresentationMarch 2017 Corporate Presentation
March 2017 Corporate Presentationoncolyticsinc
 

Ähnlich wie More than just a potential BREAKTHROUGH treatment for many cancers (20)

Critical Outcome Technologies at the BIO Investor Forum 2014
Critical Outcome Technologies at the BIO Investor Forum 2014Critical Outcome Technologies at the BIO Investor Forum 2014
Critical Outcome Technologies at the BIO Investor Forum 2014
 
COTI Corporate Presentation at Cantech 2017
COTI Corporate Presentation at Cantech 2017COTI Corporate Presentation at Cantech 2017
COTI Corporate Presentation at Cantech 2017
 
Critical Outcome Investor Presentation - March 2014
Critical Outcome Investor Presentation - March 2014Critical Outcome Investor Presentation - March 2014
Critical Outcome Investor Presentation - March 2014
 
Critical Outcome - September 2014
Critical Outcome - September 2014Critical Outcome - September 2014
Critical Outcome - September 2014
 
Critical Outcome Technologies - May 2014
Critical Outcome Technologies - May 2014Critical Outcome Technologies - May 2014
Critical Outcome Technologies - May 2014
 
Critical Outcome - Investor Presentation - January 2014
Critical Outcome - Investor Presentation - January 2014Critical Outcome - Investor Presentation - January 2014
Critical Outcome - Investor Presentation - January 2014
 
180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5
 
Viatar ctc-solutions-9-16-15
Viatar ctc-solutions-9-16-15Viatar ctc-solutions-9-16-15
Viatar ctc-solutions-9-16-15
 
VIATAR CTC SOLUTIONS
VIATAR CTC SOLUTIONSVIATAR CTC SOLUTIONS
VIATAR CTC SOLUTIONS
 
Critical Outcome Technologies - Investor Presentation - June 2013
Critical Outcome Technologies - Investor Presentation - June 2013Critical Outcome Technologies - Investor Presentation - June 2013
Critical Outcome Technologies - Investor Presentation - June 2013
 
Critical Outcome BIO Investor Forum
Critical Outcome BIO Investor ForumCritical Outcome BIO Investor Forum
Critical Outcome BIO Investor Forum
 
2017 Annual General & Special Meeting of Shareholders
2017 Annual General & Special Meeting of Shareholders2017 Annual General & Special Meeting of Shareholders
2017 Annual General & Special Meeting of Shareholders
 
Snti 102013
Snti 102013Snti 102013
Snti 102013
 
Oncology_WP_d02_web
Oncology_WP_d02_webOncology_WP_d02_web
Oncology_WP_d02_web
 
Tomorrows path-to-improved-early-phase-oncology-drug-development
Tomorrows path-to-improved-early-phase-oncology-drug-developmentTomorrows path-to-improved-early-phase-oncology-drug-development
Tomorrows path-to-improved-early-phase-oncology-drug-development
 
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...
 
1810 3 q-2018-presentation-v7
1810 3 q-2018-presentation-v71810 3 q-2018-presentation-v7
1810 3 q-2018-presentation-v7
 
Vital Signs Edition #3
Vital Signs   Edition #3Vital Signs   Edition #3
Vital Signs Edition #3
 
PTX
PTXPTX
PTX
 
March 2017 Corporate Presentation
March 2017 Corporate PresentationMarch 2017 Corporate Presentation
March 2017 Corporate Presentation
 

Kürzlich hochgeladen

Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 

Kürzlich hochgeladen (20)

Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 

More than just a potential BREAKTHROUGH treatment for many cancers

  • 1. More than just a potential breakthrough treatment for many cancers June 2015
  • 2. 22 Critical Outcome Technologies Inc. Rapidly developing targeted therapies to better meet the needs of patients  TSX-V: COT  OTCQB: COTQF
  • 3. 3 Highlights 1 2 3 COTI-2 – lead program in oncology entering Phase 1 clinical trial in 2015 CHEMSAS – proprietary drug discovery engine using machine-based learning Strong pipeline of opportunities in oncology and other therapeutic areas
  • 4. 4 COTI-2: a promising advance  Potential breakthrough treatment for many cancers  Effective against many common cancers with a p53 gene mutation  > 50% of all human cancers have a p53 mutation (eg. ~ 95% of serous ovarian cancers)
  • 5. 5 COTI-2 background N N N H S N N N  3rd generation Thiosemicarbazone  A small molecule discovered by our CHEMSAS process  Engineered for low toxicity and easily synthesized in 3 steps  Demonstrates strong in vitro and in vivo activity 5
  • 6. 6 COTI-2: first- and best-in-class potential  Novel p53-dependent mechanism of action  Orally bio-available and effective at low dose  Low toxicity in preclinical development  Opportunity for single agent and combination therapy  Strong IP protection in place
  • 7. 7 COTI-2 and tumor volumes Tumors significantly reduced by COTI-2 in all treatment groups relative to vehicle control
  • 8. 8 COTI-2 reduces p53 resistant protein levels  COTI-2 significantly reduces p53 mutant protein levels and significantly increases wild-type p53 protein levels in TOV- 112D cells likely by inducing a conformational change •(*) Significant difference in p53 protein levels between COTI-2 treated and untreated cells (control) Mutant p53 Levels in the presence/absence of COTI-2 0 20 40 60 80 100 TOV-112D H460 MeanFluorescenceIntensity(ArbitraryUnits) Cell Line Control COTI-2 *
  • 9. 9 COTI-2: effects on p53 protein levels  COTI-2 has no significant effect on p53 protein levels in the H460 cell line, which do not carry the mutant p53 protein •(*) Significant difference in p53 protein levels between COTI-2 treated and untreated cells (control) Wild-type p53 Levels in the Presence/Absence of COTI-2 0 20 40 60 80 100 120 TOV-112D H460 MeanFluorescenceIntensity(ArbitraryUnits) Cell Line Control COTI-2 *
  • 10. 10 MD Anderson relationship 10  Confirmed COTI-2’s novel p53 dependent MOA  Confirmed selective & potent anti-cancer activity  Identified effective dosage 60% lower than in prior animal experiments
  • 11. 11 COTI-2: the pathway to the clinic  Granted orphan drug status for ovarian cancer by FDA in June 2014  Completed final pre-clinical studies  Signed LOI with MD Anderson for Phase 1 clinical development  Grant of Investigational New Drug status in May 2015  Commence Phase 1 clinical trial in 3rd quarter of calendar 2015
  • 12. 12 COTI-2: next steps 12 Complete Phase 1: 46 patients in gynecologic cancers Expand indications and combination therapies Phase 2: add value – create partnerships
  • 13. 1313  Proprietary, machine learning (AI) based drug discovery platform technology  Big Data analysis solutions Building a robust pipeline with CHEMSAS®
  • 14. 14 Costly failed attempts occur quickly & cheaply in computer simulations, not the ‘wet lab’ Increased probability of clinical & commercial success Database driven computational replication of traditional ‘wet lab’ drug discovery process 14 Advantages of CHEMSAS®
  • 15. 15 Drugs in our pipeline Therapy Library /Compound Target CHEMSAS Lead Selection Synthesis Preclinical Phase 1 Oncology COTI-2 AML Colon Small Cell Lung Cancer Library COTI-219 COTI-4 COTI-58 6 other leads Plus projects for MRSA, Multiple sclerosis, Alzheimer’s, and HIV Integrase Inhibitors
  • 16. 16 Summary 1 2 3 COTI-2 – lead program in oncology entering Phase 1 clinical trial in 2015 CHEMSAS – proprietary drug discovery engine using machine-based learning Strong pipeline of opportunities in oncology and other therapeutic areas
  • 17. 17 When used anywhere in this presentation, whether oral or written, the words expects, believes, anticipates, estimates and similar expressions are intended to identify forward-looking statements. Forward-looking statements may include statements addressing future financial and operating results of Critical Outcome Technologies Inc. (COTI). COTI bases these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of potential patent issues, competition, changes in economic conditions, and other risks described in COTI’s public documents such as press releases and filings with the Toronto Stock Exchange and the Ontario Securities Commission. All forward-looking statements are qualified in their entirety by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation. Disclaimer
  • 18. Follow CriticalOutcome on Twitter, Facebook, YouTube and SlideShare